-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in China, and its incidence is the first among otorhinolaryngology malignant tumors
.
Most nasopharyngeal carcinomas have moderate sensitivity to radiotherapy, and radiotherapy is the preferred treatment for nasopharyngeal carcinoma
The incidence rate is the first of otorhinolaryngology malignant tumors
This is an open-label, randomized phase 3 clinical trial recruiting treatment-naïve nonkeratinizing nasopharyngeal carcinoma patients (18 -65 years old)
.
Patients were randomized (1:1) to receive induction chemotherapy with TPC or PF regimen followed by chemoradiotherapy
The primary endpoint was failure-free productivity
The 3-year treatment failure-free survival rates in the TPC and PF groups were 83.
In conclusion, this randomized trial showed that compared with induction chemotherapy with PF regimen, two courses of induction therapy with TPC regimen can improve the treatment failure-free survival rate of patients with stage IVA-IVB nasopharyngeal carcinoma without increasing toxicity
Compared with induction chemotherapy with PF regimen, two courses of induction therapy with TPC regimen can improve the treatment failure-free survival rate of patients with stage IVA-IVB nasopharyngeal carcinoma without increasing toxicity .
Original source:
Original Source: Original Source:Li W, Lv X, Hu D, et al.
Li W, Lv X, Hu D, et al.
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
JAMA Oncol.
Published online March 24, 2022.
doi:10.
1001/jamaoncol.
2022.
0122.
JAMA Comments Here
